嵌合抗原受体自然杀伤细胞治疗胃肠道肿瘤免疫治疗：从基础到临床。
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.
机构信息
Department of Urinary Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110032, P.R. China.
China Medical University, Shenyang, Liaoning Province, 110000, P.R. China.
出版信息
Mol Cancer. 2024 Oct 23;23(1):237. doi: 10.1186/s12943-024-02151-3.
BACKGROUND
Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as a promising alternative to CAR-T cells for immunotherapy of GI cancers. Notably, CAR-NK cells offer several advantages, including reduced risk of graft-versus-host disease, lower cytokine release syndrome, and the ability to target cancer cells through both CAR-dependent and natural cytotoxic mechanisms.
MAIN BODY
This review comprehensively discusses the development and applications of CAR-NK cells in the treatment of GI cancers. We explored various sources of NK cells, CAR design strategies, and the current state of CAR-NK cell therapy for GI cancers, highlighting recent preclinical and clinical trials. Additionally, we addressed existing challenges and propose potential strategies to enhance the efficacy and safety of CAR-NK cell therapy.
CONCLUSIONS
Our findings highlight the potential of CAR-NK cells to revolutionize GI cancer treatment and pave the way for future clinical applications.
背景
胃肠道（GI）癌症是全球范围内的重大健康负担。其发病率持续上升，其治疗仍然是临床挑战。嵌合抗原受体（CAR）自然杀伤（NK）细胞已成为胃肠道癌症免疫治疗的一种有前途的 CAR-T 细胞替代方法。值得注意的是，CAR-NK 细胞具有几个优势，包括降低移植物抗宿主病的风险、较低的细胞因子释放综合征以及通过 CAR 依赖性和自然细胞毒性机制靶向癌细胞的能力。
主要内容
本文全面讨论了 CAR-NK 细胞在胃肠道癌症治疗中的开发和应用。我们探讨了 NK 细胞的各种来源、CAR 设计策略以及 CAR-NK 细胞治疗胃肠道癌症的现状，重点介绍了最近的临床前和临床试验。此外，我们还讨论了现有的挑战，并提出了增强 CAR-NK 细胞治疗疗效和安全性的潜在策略。
结论
我们的研究结果强调了 CAR-NK 细胞在胃肠道癌症治疗方面的潜力，并为未来的临床应用铺平了道路。
Zotero 插件